Новые возможности неинвазивного лечения инфантильной гемангиомы век у детей

Abstract

Purpose. Clinical evaluation of effectiveness of transdermal application of Timolol solution 0.25% in treatment of infantile hemangioma (IH) of eyelids in infants. Material and methods. 30 infants (2 to 3 months) with IH of eyelid. In all children, the pathological process of eyelids was unilateral and was characterized by rapid growth. The course of treatment consisted of topical medication on tumor by applying betaadrenergic blocker Timolol maleate 0.25% to hemangioma area. Depending on size of hemangioma and rate of regression, duration of course of treatment varied from 2 to 6 months. Results. All 7 children with small IH of eyelid showed complete regression of the neoplasm after 3–4-month course of treatment, in all patients with medium-sized IH of eyelid – only after 5-month course of treatment. In patients with IH of eyelids large size, recovery occurred only after 6 months of treatment: in 13 children, complete normalization of position of upper eyelid was noted, and only in 3 children, ptosis decreased to functionally harmless 1st degree. Conclusion. Based on the conducted studies, topical applications of Timolol solution 0.25% in infants with IH of eyelid can be considered as safe and effective alternative to oral administration of beta-blockers and other systemically administered drugs – corticosteroids, interferon. It has been established that a non-invasive method of topical treatment of capillary IH of eyelids with a nonselective beta-blocker is clinically justified, easy to perform, administered doses of drug do not cause systemic and local complications and ensure stable tumor regression. The results of study allowed us to standardize the optimal timing of the use of Timolol maleate solution 0.25%, depending on the size of IH: for small sizes – 4 months, for medium sizes – 5 months, for large – at least 6 months. Key words: infantile hemangioma, Timolol, topical medication